Open access
Jul 2026
ES302, A Novel TL1A/IL-23p19 Bi-specific Antibody Demonstrates Robust Efficacy and Developability for Inflammatory Bowel Disease 2305836
In animal model, the ES302 showed significantly superior efficacy over monospecific therapies, markedly reducing disease activity, histopathological scoring, and pro-inflammatory cytokines, compatible with high-concentration formulation for subcutaneous administration.
Hongtao Lu, Jing Gao, Dawei Sun et al.
· Journal of Immunology · 0 citations